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esponsibility of Inst
ess under CC BY-NC-Abstract The objective of this study was to prepare cubosomal nanoparticles containing a hydrophilic
anticancer drug 5-ﬂuorouracil (5-FU) for liver targeting. Cubosomal dispersions were prepared by
disrupting a cubic gel phase of monoolein and water in the presence of Poloxamer 407 as a stabilizer.
Cubosomes loaded with 5-FU were characterized in vitro and in vivo. In vitro, 5-FU-loaded cubosomes
entrapped 31.21% drug and revealed nanometer-sized particles with a narrow particle size distribution. In
vitro 5-FU release from cubosomes exhibited a phase of rapid release of about half of the entrapped drug
during the ﬁrst hour, followed by a relatively slower drug release as compared to 5-FU solution. In vivo
biodistribution experiments indicated that the cubosomal formulation signiﬁcantly (Po 0.05) increased
5-FU liver concentration, a value approximately 5-fold greater than that observed with a 5-FU solution.
However, serum serological results and histopathological ﬁndings revealed greater hepatocellular damage
in rats treated with cubosomal formulation. These results demonstrate the successful development of
cubosomal nanoparticles containing 5-FU for liver targeting. However, further studies are required to
evaluate hepatotoxicity and in vivo antitumor activity of lower doses of 5-FU cubosomal formulation in
treatment of liver cancer.
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5-Fluorouracil (5-FU), a water-soluble ﬂuorinated pyrimidine ana-
log, is an antineoplasic agent which is widely used alone or in
combination chemotherapy regimens for the treatment of advanced
gastrointestinal cancers including hepatocellular carcinoma1. How-
ever, the clinical use of 5-FU is limited by its gastrointestinal
toxicity, hematologic side effects and severe bone marrow dis-
turbances2. Moreover, because of the short plasma half-life (10–
20 min) and the high rate of metabolism of this drug in the body, the
maintenance of a therapeutic serum concentration requires the
continuous administration of high doses3,4. Elevated plasma levels
of 5-FU can cause severe side effects and the antitumor effects of
this drug depend on exposure duration rather than plasma concen-
tration5. Previous reports indicated that sustained release formula-
tions of 5-FU6–8 and selective delivery to the tumor site9–11 not only
improve the antitumor activity but also reduce side effects of 5-FU
as compared with the clinically-available 5-FU formulation.
Glycerol monooleate (GMO) is known to spontaneously form
liquid crystalline cubic phases in excess water, consisting of
bicontinuous lipid bilayers extending in three dimensions, separat-
ing two networks of water channels12. Due to GMO's unique
structure, cubic phases are able to incorporate and control the
release of drugs of various molecular weights and polarities13–16.
Three macroscopic forms of cubic phase are typically encountered:
precursor, bulk and particulate (i.e., cubosomes). Precursor mate-
rials are usually liquid and form cubic phase only in response to
some stimulus, like dilution17,18. Bulk forms of cubic phase are
viscous liquid crystalline materials, usually hydrated monoolein,
often with a drug incorporated in their structure19. The high
viscosity, biodegradability, ability to incorporate and deliver drugs
of varying sizes and water solubilities and the ability to enhance
the chemical and/or physical stability of the incorporated drugs
make the bulk cubic gel an excellent candidate for use as a drug
delivery matrix. However, the high viscosity and stiffness of the
cubic gel limit its potential use as the delivery system by itself16.
The emulsiﬁcation of the cubic lipid phases in water results in
the production of cubosomes that can be deﬁned as nanoparticulate
dispersal systems characterized by high biocompatibility and
bioadhesivity20. It has been demonstrated that the dispersed
particles retain the internal structure of the bulk phase and its
properties. Because of their properties, these versatile delivery
systems can be administered by different routes (i.e., orally,
parenterally or percutaneously)21. In comparison with the bulk
gel, cubosomal dispersions present some advantages, such as a
larger surface area and high ﬂuidity (low viscosity)22. However,
due to their extremely small size (and the resulting short diffusion
pathways) cubosomes are unlikely to offer similar opportunities to
control drug release as bulk cubic phases do23. In addition, the
large amount of water present during cubosomes formation renders
the incorporation of water-soluble drugs difﬁcult24.
This work describes a simple method for preparation of cubic
phase gel matrix containing small molecular weight hydrophilic
drug (5-FU) that could be dispersed with water to form a
cubosomal nanoparticle dispersion prior to subcutaneous admin-
istration. The 5-FU-loaded cubosomes were evaluated for their
in vitro and in vivo characteristics in an attempt to explore their
potential as a targeted drug delivery system that could provide a
maximum concentration of 5-FU in the liver tissues. This is
expected to improve the efﬁcacy of low doses of the drug and to
minimize the side effects associated with the higher doses of 5-FU
when used in treatment of hepatocellular carcinoma.2. Materials and methods
2.1. Materials
Myverols 18–99 K, as a source of monoolein, was a gift from
Kerry Ingredients & Flavours (Zwijndrecht, Netherlands). Polox-
amer 407 and 5-FU were purchased from Sigma-Aldrich Chemical
Company (Milwaukee, USA). Milli-Q puriﬁed water was used for
all experiments. Other reagents were of analytical grade.
2.2. Preparation of blank and 5-FU-loaded cubic gel
For blank cubic gel, GMO (2.25 g) and poloxamer 407 (0.25 g)
were melted at 70 1C in a water bath. The obtained molten solution
was added dropwise to 4 mL of deionized water (70 1C) and
vortex mixed at high speed at room temperature to achieve
homogenous state. The mixture was equilibrated at room tempera-
ture for 48 h to obtain the cubic gel. The drug-loaded cubic gel
was prepared by dissolving 50 mg of 5-FU in 4 mL deionized
water before addition of the GMO/poloxamer 407 molten solution.
The remaining process followed the same steps as described for
preparation of blank cubic gel. The cubic gels were stored at
ambient temperature until required.
2.3. Preparation of cubosomal nanoparticles dispersions
To prepare the cubosomal dispersion, the cubic gel was dispersed
with 18.50 mL deionized water by vortex at high speed for 3 min.
The ﬁnal concentration of lipid in the dispersion is 10% (w/w) with
respect to the ﬁnal dispersion weight. The ﬁnal 5-FU concentration
in cubosomal dispersion was 2 mg/g cubosomal dispersion.
2.4. Characterization of cubosomes
2.4.1. Morphology of cubosomes
Morphological examination of cubosomal nanoparticles was
carried out using a transmission electron microscope (FEI, The
Netherlands), modal: Tecani G20 equipped with super twin lens,
a LaB6 electron source and operated at 60 kV. A droplet of
cubosomes dispersion was placed on a 200 mesh carbon-coated
copper grid, and the excess ﬂuid was removed by an absorbent
ﬁlter paper. The samples were stained with 1% sodium phospho-
tungstate solution and were viewed using magniﬁcation up to
1,000,000.
2.4.2. Particle size analysis
The particle size distribution (Z-average) and polydispersity index
(PDI) of cubosomal dispersions were determined by dynamic light
scattering using Zeta Sizer Nano-series (Nano ZS, Malvern,
Worcestershire, UK). Samples were diluted (100-fold) with
deionized water and measured at 2570.5 1C in triplicate.
2.4.3. Entrapment efﬁciency
The drug entrapment efﬁciency was determined by ultraﬁltration
centrifugation25. 1 mL of freshly prepared 5-FU loaded cubosomal
dispersion was diluted to 10 mL with deionized water and 3 mL of
the diluted samples was placed in centrifuge tubes (Amicon Ultra
3000 MWCO, Millipore, USA) and centrifuged at 4000 rpm for
15 min. As some drugs are adsorbed to the ultraﬁltration mem-
brane to a certain extent26, the drug adsorption to the ultraﬁltration
membrane was investigated by ﬁltration of simple drug solution of
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concentrations in the ultraﬁltrate. Free 5-FU contained in ﬁltrate
was measured spectrophotometrically at λmax¼266 nm. The
amount of entrapped 5-FU was obtained by subtracting the amount
of free drug from the total drug incorporated in 1 mL cubosomal
dispersion. The total amount of 5-FU incorporated in 1 mL
cubosomal dispersion was determined after addition of 9.0 mL
methanol to dissolve the drug loaded-cubosomes. The resultant
solution was assayed for the total 5-FU content spectrophotome-
trically using methanol as blank. The entrapment efﬁciency (EE)
was calculated as follows:
EE ð%Þ ¼Amount of drug entrapped=Total amount of drug 100
2.4.4. Differential scanning calorimetry (DSC)
To detect any possible change in the physical state of 5-FU
entrapped in the cubic gel, DSC was performed on 5-FU-loaded
cubic gel, blank cubic gel, pure 5-FU powder, GMO and
poloxamer 407 using a thermal analysis system (DSC-60, Shi-
madzu, Japan). The samples (5 mg) were heated at a constant rate
of 10 1C/min in an aluminum pan under a nitrogen atmosphere.
A similar empty pan was used as the reference.
2.4.5. X-ray diffraction
X-ray diffraction patterns of the prepared cubic gels as well as pure
5-FU, GMO and poloxamer 407 samples were obtained using the
X-ray diffractometer (X'Pert-PRO Diffractometer, PANalytical,
Netherlands) with Cu as tube anode. The diffractograms were
recorded under the following conditions: the voltage 45 kV, the
current 30 mA, the steps 0.021 and the counting rate 0.5 s/step at
room temperature. Data were collected using scattering angle (2θ)
ranged 4–501.
2.4.6. In vitro drug release from cubosomes
In vitro release of 5-FU from cubosomes was evaluated using a
dynamic dialysis method27. The release rate of drug was deter-
mined after separation of free drug from drug-loaded cubosomes
by placing the cubosomal dispersion in dialysis tubing (10,000
MWCO, Millipore, Boston, USA) and exhaustively dialyzed for
15 min for several times, each time against 100 mL of phosphate
buffer (pH 7.4)28. The dialysis of free 5-FU was completed after
1 h after which no further drug could be detected in the solution.
The dialyzed suspension containing 5-FU-loaded cubosomes
(equivalent to 1 mg drug) or plain drug aqueous solution was
sealed in a dialysis bag (10,000 MWCO, Millipore, Boston, USA).
The dialysis bag was then immersed in 100 mL of phosphate
buffer (pH 7.4) thermostatically maintained at 3770.5 1C and
magnetically stirred at 50 rpm. The samples (3 mL) were with-
drawn at various time intervals and analyzed by a UV spectro-
photometer at 266 nm. Volumes lost by sample withdrawal were
replaced with fresh medium. The experiments were conducted in
triplicate.
2.5. Stability study
The stability study was carried out on cubic gel containing 5-FU.
Samples of cubic gel were stored in tightly closed amber colored
glass vials sealed with aluminum foil at refrigeration temperature
4–8 1C for a period of 3 months. The samples were withdrawn at
the end of the study period and were dispersed in deionized waterby vortex for 3 min. The prepared cubosomal dispersion was
subjected for mean particle size and EE (%) measurements. All
reported particle size and EE (%) data are the mean of three
separate measurements.2.6. In vitro cytotoxicity of 5-FU-loaded cubosomes
Samples were supplied to the Bioassay-Cell Culture Laboratory
(National Research Centre, Cairo, Egypt) to determine the in vitro
cytotoxicity of 5-FU cubosomal dispersion (containing free drug
and 5-FU-loaded cubosomes) compared to 5-FU solution.
The in vitro cytotoxicity was performed by the mitochondrial
dependent reduction of yellow MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) to purple formazan29. MTT cell
viability assay was carried out with human hepatoma HepG2 cell
line. Cells were suspended in RPMI 1640 medium containing 1%
antibiotic–antimycotic mixture (10,000 U/mL potassium penicillin,
10,000 mg/mL streptomycin sulfate and 25 mg/mL amphotericin
B), 1% L-glutamine and 10% fetal bovine serum and kept at 37 1C
under 5% CO2. Cells were batch cultured for 10 days, then seeded
at concentration of 1 104 cells/well in fresh complete growth
medium in 96-well microtiter plastic plates at 37 1C for 24 h under
5% CO2 using a water jacketed carbon dioxide incubator (Sheldon,
TC2323, Cornelius, USA). Media was aspirated, fresh medium
(without serum) was added and cells were incubated either alone
(control) or with different concentrations of samples to give a ﬁnal
concentration (100, 50, 25 and 12.5 μg/mL) of 5-FU. After 48 h of
incubation, medium was aspirated; 40 μL MTT salt (2.5 μg/mL)
was added to each well and incubated for further 4 h at 37 1C
under 5% CO2. To stop the reaction and dissolving the formed
crystals, 200 μL of 10% sodium dodecyl sulfate in deionized water
was added to each well and incubated overnight at 37 1C. The
absorbance was then measured using a microplate multi-well
reader (Bio-Rad Laboratories Inc., model 3350, Hercules, USA)
at 595 nm and a reference wavelength of 620 nm. Cell viability
was calculated as the percentage of absorbance in wells with the
treated cells to that of control cells. A probit analysis was carried
for IC50 (the concentration that inhibited cell growth by 50%)
determination using SPSS 11 program.2.7. In vivo evaluation of 5-FU-loaded cubosomes
The protocol of the in vivo studies was approved by the Animal
Ethics Committee of Faculty of Pharmacy, Helwan University.
The study was conducted in accordance with EC Directive 86/609/
EEC for animal experiments.2.7.1. Biodistribution of 5-FU in rat liver
Eighteen adult male Wistar rats weighing 160–180 g were used in
the study. All rats were housed and received similar diet. The rats
were divided randomly into 2 groups; each was of 9 rats and all
rats were fasted overnight for 12 h with free access to water. On
the day of experiment, each rat in group 1 received a single
subcutaneous dose of 10 mg/kg of plain 5-FU solution in
phosphate-buffered saline and rats in group 2 received the same
equivalent doses of 5-FU cubosomal dispersion containing
both 5-FU-loaded cubosomes and free 5-FU. The use of cuboso-
mal dispersion was the possible practical solution to attain the
required dose of 5-FU in a suitable volume for subcutaneous
administration.
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sacriﬁced by cervical dislocation. The rats were dissected, and
their livers were removed and rinsed with saline solution to
remove any adhered debris, blotted dry with ﬁlter paper. 1 g of
liver tissue was homogenized (Yellow-Line disperser, IKAs
Works, Inc., USA) in 3 mL phosphate buffer saline (pH 7.4).
The homogenate was centrifuged at 6000 rpm at 4 1C for 30 min
to obtain supernatant. The supernatant of liver homogenate was
kept frozen until analysis.2.7.2. Analysis of 5-FU concentration
5-FU concentration in the supernatant of liver homogenate was
quantiﬁed by a reported liquid chromatography–tandem mass
spectrometry (LC-MS/MS) method30 with slight modiﬁcations.
Samples (500 μL) was mixed with 50 μL of ammonia and
extracted with 6 mL of ethyl acetate. After centrifugation at
5000 rpm for 5 min, 3 mL of the organic layer was evaporated
to dryness. The residue was redissolved in 250 μL of the mobile
phase and the obtained solution was ﬁltered and a volume of 10 μL
ﬁltrate was injected into the LC-MS/MS system.
The LC system consisted of a Thermo Fisher Scientiﬁc (San
José, USA) Accela HPLC 1200 LC-10AD pumping system,
coupled with an Accela autosampler and a Hypersil Gold C18
column (50 mm 2.0 mm, 2.1 mm, Phenomenex) preceded by a
Gemini C18 (4 mm 3 mm, 5 μm) security guard cartridge
(Phenomenex). Separation and elution were achieved using
acetonitrile: 0.1% formic acid (90:10, v/v) as the mobile phase at
a ﬂow-rate of 0.25 mL/min for a run time of 2 min. Mass
spectrometric analysis is carried out using a TSQ Quantum Access
AX triple quadrupole mass spectrometer. Data acquisition for
quantiﬁcation and conﬁrmation is performed in Full scan mode.
Samples are individually tuned for each target analyte by direct
injection of the individual solution (1 mg/mL). The following
working conditions were applied: ionization mode: Heated Elec-
trospray (HESI); polarity: positive ion mode; spray voltage: 300 V;
vaporizer and capillary temperature at 400 and 370 1C, respec-
tively; sheath and auxiliary gas pressure at 25 and 5 arbitrary units,
respectively; cycle time: 0.7 s. Peak width: full width of a peak at
half its maximum height (FWHM) of 0.70 Da. The lower limit of
quantiﬁcation was 0.1 mg/mL. The standard calibration curve for
5-FU was linear (correlation coefﬁcients were 40.9997) over the
studied concentration range (0.4–10 mg/mL). Instrument control,
data acquisition and data evaluation were performed using Thermo
Scientiﬁc Xcalibur 2.1 software.2.7.3. Liver function and histopathological examination
The main objective of this experiment was to evaluate the effect of
5-FU cubosomal formulation on rat's liver function parameters and
the possible histopathological change in liver tissues compared to
free 5-FU solution. For this study, 12 male Wistar rats weighing
175–190 g were divided into 4 groups each containing 3 rats. The
rats in groups 1 and 2 were treated subcutaneously with 10 mg/kg
of free 5-FU aqueous solution and the same equivalent dose of
5-FU cubosomal dispersion for 7 days. The rats in group 3
received equivalent dose of blank cubosomal dispersion (negative
control). The remaining group received no medication (normal
control). Blood samples were collected from all rats after 7 days of
treatment. Serum levels of liver enzymes, aspartate aminotransfer-
ase (AST) and alanine aminotransferase (ALT), were estimated by
kinetic method using semiautomatic analyzer BTS-350 (BioSys-
tems, Spain). At the end of the study, all the rats were sacriﬁced bycervical dislocation; livers were excised and transferred in 10%
formalin saline solution for histopathological examination.
Autopsy samples were taken from the liver of rats in the different
groups and ﬁxed in 10% formal saline for 24 h. Washing was done
in tap water then serial dilutions of alcohols (methyl, ethyl and
absolute ethyl) were used for dehydration. Specimens were cleared
in xylene and embedded in parafﬁn at 56 1C in a hot oven for 24 h.
Parafﬁn bees wax tissue blocks were prepared for sectioning at
thickness of 4 μm by sliding microtome. The obtained sections
were collected on glass slides, deparafﬁnized and stained by
hematoxylin and eosin stain for routine examination through
electric microscope31.
2.8. Statistical analysis
In order to compare the results, Student's t-test (SPSS program;
version 12.0) was used. Stability data were compared using paired
t-test. Data reported as mean7standard deviations (SD). A statis-
tically signiﬁcant difference was considered at P o 0.05.3. Results and discussion
3.1. Preparation of cubosomes
Blank and 5-FU-loaded cubosomal nanoparticle dispersions were
prepared through disrupting a cubic gel phase of GMO and water
in the presence of poloxamer 407 as a stabilizer by mechanical
stirring. The dispersions appeared as uniform opaque white
mixtures with no visible signs of aggregate. The ﬁnal concentra-
tion of lipid in the dispersion was 10% w/w with respect to the
ﬁnal dispersion weight. The ratio of GMO to poloxamer 407 in
total lipid content was 9:1 w/w. The choice of this ratio was based
upon observations of Jin et al.32 who found that cubosomes of this
composition have reasonable physicochemical properties and
improved the absorption of a poorly absorbed drug.
3.2. Characterization of cubosomes
The morphological examination of 5-FU cubosomal nanoparticles
was performed using TEM. The photograph (Fig. 1) reveals that
the drug-loaded cubosomal nanoparticles are nearly spherical with
irregular polyangular shapes without aggregation. However, the
particle diameters are smaller than those showed by particles size
measurement determined by a dynamic light scattering particle
size analyzer.
EE (%) of 5-FU in cubosomes was determined after separation
of the free 5-FU from cubosomal nanoparticles loaded with the
drug by ultraﬁltration centrifugation. Drug adsorption to the
ultraﬁltration membrane was insigniﬁcant as reﬂected by nearly
100% recovery of the tested drug concentrations. The EE (%) was
(31.2172.83)%, which revealed that most of the drug was not
entrapped in the cubosomes. Similar EE (%) values of 5-FU were
previously reported with other lipid based vesicular delivery
systems of 5-FU such as niosomes28 and liposomes33,34. The
low EE (%) of 5-FU may be attributed to the extensive mobile
character of the small 5-FU molecule, which does not associate
with the lipid bilayer35. Moreover, due to the hydrophilic nature
of 5-FU molecules (logPoctanol/water¼0.89)36 and its limited
solubility (approximately 0.13%, w/w) in GMO, 5-FU was expected
to be entrapped within the aqueous channels of cubosomal
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drug from the aqueous channels to the surrounding aqueous phase
during the preparation and centrifugation processes37. Previous
studies reported that even lipophilic drugs were rapidly released
from cubosomes after ultraﬁltration38.
The results of particle size and polydispersity index of the
prepared cubosomes are presented in Table 1. Mean particle sizes
of blank and 5-FU-loaded cubosomes were 91.2874.54 nm and
105.7075.47 nm, respectively. Both dispersions displayed a
narrow monomodal particle size distribution (Fig. 2). The value
obtained for particle size may be attributed to the use of a
relatively high concentration of poloxamer 407 (10%, w/w relative
to the dispersed phase) as a stabilizer. The polydispersity indices
of blank and 5-FU-loaded cubosomal dispersions were
0.34370.056 and 0.42970.154, respectively. These relatively
high values for both dispersions may be attributed to the
coexistence of cubosomes with other type of vesicles in the
cubosomal dispersion as previously reported39,40. The presence of
predominantly vesicular structures at high poloxamer 407 con-
centrations may be due to the formation of mixed monoolein/
poloxamer bilayers which sterically stabilize the particles against
their fusion into the cubic state41. Although comparatively high
poloxamer 407 concentrations are beneﬁcial in terms of formation
of smaller particles, they also promote formation of vesicular
particles over formation of the desired particles of cubic
structure42.
Fig. 3 shows the DSC thermograms of 5-FU, GMO, poloxamer 407,
blank cubosomes and 5-FU-loaded cubosomes. It is clear that the DSC
thermogram of 5-FU exhibits a single sharp characteristic, endothermic
melting peak at 281.6 1C which is in agreement with that reportedFigure 1 TEM images of population of drug loaded cubosomes (a)
and a magniﬁed single cubsome (b).
Table 1 Entrapment efﬁciency (EE), particle size and polydispersity
Formulation EE (%)
Blank cubosomes –
5-FU-loaded cubosomes 31.2172.83
Data are expressed as mean7SD, n¼3.previously43. However, 5-FU melting peak completely disappeared in
thermogram of 5-FU-loaded cubosomes. This indicates that the drug
incorporated in the cubosomes existed in a non-crystalline state.
X-ray diffraction (Fig. 4) was carried out to conﬁrm the
physical state of 5-FU loaded into cubosomes in comparison to
drug-free cubosomes, pure 5-FU, GMO and poloxamer 407. It is
clear that the diffractogram of the pure 5-FU exhibited character-
istic intensity reﬂections counts of 898, 1448 and 706 at diffraction
angles of 9.511, 29.791 and 33.471 (2θ), respectively, indicating its
crystalline nature. However, these characteristic peaks disappeared
in the X-ray diffraction pattern of 5-FU-loaded cubosomes.
Moreover, the powder X-ray diffraction pattern for the drug
loaded cubosomes was without any remarkable difference when
compared to the powder X-ray pattern for blank cubosomes. This
indicates that the drug was molecularly dispersed or in non-
crystalline state and conﬁrms previous results from the DSC
analysis.
Results of 5-FU in vitro release from 5-FU-loaded cubosomes
compared to 5-FU aqueous solution are illustrated in Fig. 5A.
A rapid and complete release from 5-FU aqueous solution was
obtained after 1 h. The release proﬁle of 5-FU from cubosomes
was biphasic, with an initial burst release of approximately
(53.6073.55)% of drug during the ﬁrst hour, followed by a
relatively slow drug release of the remaining drug after 4.5 h. The
higher initial burst release is mainly attributed to weakly bound orindex (PDI) of blank and 5-FU-loaded cubosomes.
Particle size (nm) PDI
91.2874.54 0.34370.056
105.7075.47 0.42970.154
Figure 2 Particle size distributions of blank and 5-FU-loaded
cubosomes.
Figure 3 DSC thermograms of (A) pure 5-FU, (B) 5-FU-loaded
cubosomes, (C) blank cubosomes, (D) Poloxamer 407 and (E) GMO.
Figure 4 X-ray diffractograms of (A) pure 5-FU, (B) 5-FU-loaded
cubosomes, (C) blank cubosomes, (D) Poloxamer 407 and (E) GMO.
Figure 5 (A) In vitro release proﬁles of 5-FU from aqueous solution
and cubosomes in pH 7.4 phosphate buffer (mean7SD, n¼3). (B)
Cumulative release of 5-FU from aqueous solution and cubosomes
(mean7SD, n¼3) vs. the square root of the time.
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Moreover, in our case, the low afﬁnity of 5-FU to the hydrophobic
domain in the cubosomes made it easy to be released faster
through diffusion from aqueous channels. The burst release of
hydrophilic and hydrophobic drugs from cubosomes was pre-
viously reported38,45. On the other hand, the relatively slow release
of 5-FU observed from cubosomes may be attributed to the limited
diffusion of drug molecules incorporated in the aqueous channels;
in this case diffusion is governed by the tortuosity and the
relatively narrow pore size of the aqueous channels46,47. The
potential of cubosomes to provide a slow release matrix for drugs
of varying sizes and polarity has been reported48–52. However, the
present results demonstrate that the overall release of 5-FU from
cubosomes is relatively rapid compared to the reported slow and
sustained release of other drugs incorporated into cubosomes53,54.
It should be noted that the latter drugs are considerably more lipid
soluble than 5-FU, a water soluble compound. The presently-
documented release of cubosomal 5-FU is also rapid as compared
with the release of 5-FU from other drug delivery systems6–11.
To emphasize the diffusion controlled release of 5-FU, the
release data were plotted vs. the square root of time (Fig. 5B).
A linear relationship was found for both free 5-FU aqueous
solutions and 5-FU-loaded cubosomes with correlation coefﬁcients
of 0.985 and 0.992, respectively, indicating that the diffusion is the
dominant mechanism of release55. These results are consistent with
other reports of drug release from cubosomal nanoparticles49,50,56.
3.3. Stability study
Studies of in vitro release revealed that the release of 5-FU from the
cubosomal nanoparticles is quite rapid; this could limit the storage
time of the cubosomal dispersion. Therefore, the cubic gel contain-
ing 5-FU was prepared and stored until disrupted with water using
vortex to prepare the cubosomal dispersion just before its use. After
3 months of storage of the cubic gel containing 5-FU at refrigera-
tion temperature (4–8 1C), the cubosomal dispersion was prepared
to measure the particle size and EE (%). The mean particle size
(7SD, n¼3) increased from 105.7075.47 nm to 112.3472.6 nm.
The mean EE% (7SD, n¼3) decreased from (31.2172.83)% to
(29.1170.62)%. The slight increase in the mean particle size and
decrease in EE (%) were found to be statistically insigniﬁcant
(P40.05, paired t-test), indicating that storage of cubic gel in
tightly closed amber glass containers at refrigerator temperature
(4–8 1C) did not adversely affect either the particle size or EE (%)
of the prepared cubosomal dispersion. The ability of the GMO
cubic phase gel to protect small, labile drugs (such as cefazolin and
cefuroxime) from chemical instability reactions (such as hydrolysis
and oxidation) was previously reported57.
3.4. In vitro cytotoxicity of 5-FU-loaded cubosomes
Cytotoxicity of 5-FU cubosomal formulation was evaluated in
human hepatoma HepG2 cell line and compared to the effects of
blank cubosomes and free 5-FU aqueous solutions. The
concentration-dependent cell viability curves are presented in
Fig. 6. The half-maximal inhibitory concentrations (IC50) were
107.78 mg/mL and 112.70 mg/mL for 5-FU cubosomal dispersion
and free 5-FU, respectively. The difference between the mean IC50
values was found to be statistically insigniﬁcant (P40.05) when
analyzed using student's t-test. Accordingly, 5-FU cubosomal
formulation has an equally efﬁcient cytotoxic activity as compared
Figure 6 Cell viability of HepG2 cell line treated with blank, 5-FU
cubosomal dispersion and 5-FU solution for 48 h at 37 1C (n¼3). Figure 7 Mean 5-FU concentrations (7SD, n¼3) in rat liver tissues
at various time intervals after subcutaneous injection of a single dose
(10 mg/kg) of free 5-FU solution and cubosomal dispersion.
Table 2 Serum levels of hepatic enzymes (AST and ALT) in
rats of different groups after 7 days.
Group AST (U/L) ALT (U/L)
n n
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antitumor activity of 5-FU is not negatively affected when the drug
is incorporated into cubosomes. The relatively low cytotoxic effect
of blank cubosomes as compared to 5-FU cubosomal formulation
indicates that blank cubosomes are not cytotoxic to human
hepatoma HepG2 cell line. Thus, the cytotoxicity of 5-FU-
loaded cubosomes is primarily due to the effect of 5-FU present
in cubosomes.5-FU solution 136.6477.32 85.7675.56
5-FU cubosomal
dispersion
255.4577.23n,# 163.1276.78n,#
Blank cubosomes 96.5475.45 51.8974.22
Control 95.3274.56 49.6473.35
Data are expressed as mean7SD, n¼3.
nPo0.001 vs. blank cubosomes and control.
#Po0.001 vs. 5-FU solution.3.5. Biodistribution of 5-FU in rat's liver
The mean 5-FU concentration in rat liver tissues at various time
intervals after subcutaneous injection of a single dose (10 mg/kg)
of free 5-FU solution and cubosomal dispersion is shown in Fig. 7.
In the case of 5-FU solution, after 1 h, the liver 5-FU concentration
was 7.1471.52 μg/g and declined rapidly to 3.9470.46 and
1.7070.24 μg/g after the 2nd or 3rd hour, respectively. Such
rapid decline of 5-FU level might have resulted from the highest
accessibility of free 5-FU to its metabolizing enzymes. On the
other hand, 5-FU-loaded cubosomes showed a gradual increase of
5-FU liver concentration from 4.7070.85 μg/g at the ﬁrst hour to
6.0471.02 and 8.4071.66 μg/g after 2 and 3 h, respectively. The
5-FU concentration in liver at 3 h after subcutaneous administra-
tion of cubosomal formulation was nearly 5-fold that observed in
case of 5-FU solution. The higher 5-FU liver concentration
associated with the cubosomal formulation might be due to the
higher systemic absorption of the 5-FU-loaded cubosomal nano-
particles from subcutaneous tissues. The enhanced systemic
absorption of cubic nanoparticles-associated drugs might be
attributed to the higher permeability of the epithelial membrane
to cubosomes as a result of the structural similarity of the lipid
bilayer of cubosomes to the microstructure of the cell mem-
brane58,59. Moreover, the systemically circulated 5-FU-loaded
cubosomal nanoparticles are susceptible to preferential phagocytic
uptake of the reticuloendothelial system in the liver tissues. These
results suggest that cubosomal formulation of 5-FU may exhibit
therapeutic activity in the liver for a prolonged period compared to
the aqueous solution.
The size of a nanoparticle is very important for drug delivery, as
the spaces between the cells in various tissues are different. For
example, it is now known that the aperture of the vascular
endothelium within most normal tissues is 2 nm, and the aperture
of the postcapillary venule is 6 nm. In contrast, the aperture of non-
continuous tumor blood vessels ranges from 100 nm to 780 nm60,61.Therefore, in treatment of hepatocellular carcinoma, the size of
5-FU-loaded cubosomal nanoparticles (105.7075.47 nm) could
allow the nanoparticles to enter the space within tumor cells but
restrict drug penetration into normal tissues. This is expected to
enhance the efﬁcacy and minimize the systemic side-effects of 5-FU
in treatment of liver cancer.
3.6. Liver function and histopathological alteration
3.6.1. Liver function
5-FU was found to produce liver toxicity associated with a number
of abnormalities62. Serum levels of hepatic enzymes (AST and
ALT) were determined to evaluate the liver function after
treatment of rats with 5-FU cubosomal dispersion, blank cubo-
somes and free 5-FU solution. An abnormal rise in either AST or
ALT levels indicates liver dysfunction or damage. From Table 2,
levels of AST and ALT were signiﬁcantly (Po0.001) increased in
rats treated with either 5-FU-loaded cubosomes or free 5-FU
solution when compared with those in the normal and negative
control groups, indicating the toxicity of 5-FU on the liver in both
groups. However, rats treated with 5-FU-loaded cubosomes
developed higher hepatocellular damage as evident from the
signiﬁcantly (Po0.001) higher levels of AST and ALT when
compared with rats treated with free 5-FU. The signiﬁcant
elevation in AST and ALT levels would be attributable to the
higher 5-FU concentration in hepatic tissues of rats treated with
Mohamed Nasr et al.86cubosomal formulation. Therefore, histopathological examination
of livers from treated and control groups was performed for further
evaluation.3.6.2. Histopathological alterations
The histopathology of the liver tissues of control, 5-FU cubosomal
formulation and free 5-FU treated rats is shown in Fig. 8. The
histology studies of control liver (Fig. 8A) showed a normal
histological structure of the central vein (CV), portal area (A) and
surrounding hepatocytes (H). In contrast, rats treated with 5-FU-
loaded cubosomes (Fig. 8B and C) showed severe dilation and
congestion in central vein (CV) and portal vein (PV) as well as
hepatic sinusoids (S). In addition, fatty changes in some of the
hepatocytes (arrow) and inﬁltration of inﬂammatory cells between
the hepatocytes in the portal area were also noted. As compared
with the effects of 5-FU-loaded cubosomes, the free 5-FU treated
group showed only mild congestion in the central and portal veins
(Fig. 8D) associated with fatty changes and ballooning degenera-
tion in the hepatocytes (arrow, Fig. 8E) at the periphery of the
hepatic parenchyma. This pattern suggests lower hepatotoxicity
from the free 5-FU group as compared with the 5-FU-loadedFigure 8 Histological appearance of liver tissues in (A) normal control g
free 5-FU solution treated group (H&E staining, 16). CV, central vein; P
sinusoids. Arrow, fatty change and ballooning degeneration in the hepatoccubosome group. The severity scores of histopathological
alterations in the livers of different groups (Table 3) were
moderate to severe in rats treated with 5-FU cubosomal formula-
tion and were mild to moderate in rats treated with free 5-FU
compared to control rats. These results indicate that the cubosomal
formulation increases the hepatotoxicity of 5-FU that could be
attributed to the higher 5-FU concentration in the liver tissues.
These results were in contrary with Cheng et al.10 who demon-
strated that the damage of liver function caused by 5-FU can be
reduced when 5-FU was formulated as galactosylated chitosan/5-FU
nanoparticles. However, further studies are required to evaluate
hepatotoxicity and in vivo antitumor activity of lower doses of 5-FU
cubosomal formulation in treatment of hepatocellular carcinoma.4. Conclusions
5-FU, a hydrophilic anticancer drug, was successfully incorporated
into cubosomal nanoparticles. Cubosomes loaded with 5-FU
exhibited a nanometer-size particles with narrow particle size
distribution. In vivo, biodistribution studies of 5-FU in rat liver
indicated that the cubosomal formulation signiﬁcantly increasedroup; (B), (C) 5-FU cubosomal dispersion treated group and (D), (E)
V, portal vein; A, portal area; H, surrounding hepatocytes; S, hepatic
ytes.
Table 3 Severity scores of the histopathological alterations in the livers of different groups.
Group Congestion Fatty change Inﬂammatory reactions
Control   
5-FU cubosomal dispersion þþþ þþ þþ
5-FU solution þ þþ 
þþþ Sever, þþ Moderate, þ Mild, – Nil. n¼3.
Cubosomes containing 5-ﬂuorouracil for liver targeting 875-FU liver concentration (nearly 5-fold) as compared to that of a
5-FU solution. On the other hand, histology studies indicated that
the increased 5-FU concentration in the liver tissues resulted in a
higher hepatocellular damage. Based on the previous results, the
use of cubosomes as a drug delivery system is expected to improve
the efﬁcacy of low doses of 5-FU. Further studies are required to
evaluate hepatotoxicity and in vivo antitumor activity of lower
doses of 5-FU in cubosomal formulations for the treatment of
hepatocellular carcinoma.References
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